IVI-guided Versus Angiography-guided PCI in Patients With Diabetes Mellitus
- Conditions
- Diabetes
- Registration Number
- NCT06380868
- Brief Summary
Intravascular ultrasound (IVUS) serves as a beneficial instrument during percutaneous coronary intervention (PCI) procedures, affording insight into lesion characteristics and stent implantation. The ULTIMATE trial recently evidenced that IVUS-guided Drug-Eluting Stent (DES) implantation notably ameliorated clinical outcomes in all-comers, especially in patients who underwent an optimal procedure defined by IVUS, as opposed to angiography guidance, resonating with findings from the IVUS-XPL study, OCTOBER trial, and RENOVATE COMPLEX PCI trial, further confirmed by more recent IVUS-ACS trial.
Optical coherence tomography (OCT) has a resolution 10 times higher than that of IVUS and can provide valuable information at each step of PCI.
Regrettably, a dearth of prospective, randomized, multicenter trials exists that scrutinize the benefits of IVI-guided as opposed to angiography-guided PCI in patients suffering from diabetes mellitus. However, several trials have presented subgroup analyses reporting the reduction of clinical events by IVUS but not OCT guidance in patients with diabetes mellitus, which served as the foundation for the design of this trial.
- Detailed Description
The current study hypothesizes that IVI-guided PCI will be superior with respect to target vessel failure (TVF), including cardiac death, target-vessel myocardial infarction (TVMI), or clinically-driven TVR when compared with angiography-guided PCI in patients with diabetes mellitus.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1332
- Age between 18 ~ 80 years old,
- Confirmed diabetes mellitus
- Indications for undergoing percutaneous coronary intervention using a drug-eluting stent (Invasive or quantitative fractional flow reserve (QFR or FFR) <0.80)
- Silent angina, stable angina, unstable angina, or Non-ST-elevation myocardial infarction
- Cardiogenic shock
- Previous coronary artery bypass graft (CABG)
- Left ventricular ejection fraction < 30%
- Requiring oral anticoagulation medications
- Any planned surgery within 12 months
- Severe chronic kidney disease defined as an estimated glomerular filtration rate (eGFR) < 20 ml/min/1.73m2
- Platelet count < 100,000 mm3
- Contraindication to study medications or metal
- Women of childbearing potential
- Life expectancy < 1 year
- Any condition likely to interfere with study processes including medication compliance or follow-up visits (e.g. dementia, alcohol abuse, severe frailty, long distance to travel for follow-up visits, etc.)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Rate of target vessel failure (TVF) At one-year since interventions TVF is defined as a composite of cardiac death, target-vessel myocardial infraction, or clinically driven target vessel revascularization
- Secondary Outcome Measures
Name Time Method Rate of target vessel failure without procedure-related MI At one-year since interventions Procedural-related myocardial infarction (PMI) would be excluded from the calculation of TVF
Rate of procedure-related myocardial infarction (PMI) Within 48 h since coronary intervention 48 hours after coronary intervention
Rate of cardiac death At one-year since interventions Any death without clear reasons
Rate of all-cause death At one-year since interventions Any death occurs within one-year follow-up
Rate of spontaneous myocardial infarction (SMI) Within one-year follow-up MI happens between 48 h and one-year since coronary intervention
Rate of clinically-driven revascularization At one-year since coronary artery intervention Target vessel revascularization was defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel was defined as the entire major coronary vessel proximal and distal to the target lesion, which included upstream and downstream branches and the target lesion itself.
Rate of stent thrombosis At one-year since coronary artery intervention Definite or probable stent thrombosis
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Nanjing First Hospital
🇨🇳Nanjing, Jiangsu, China
Nanjing First Hospital🇨🇳Nanjing, Jiangsu, ChinaShuli M Zhao, MDContact+86-25-52271003shuliz@126.comLing F Lin, MDSub InvestigatorJun-Jie M Zhang, PhDPrincipal InvestigatorFei M Ye, MDSub InvestigatorYue F Gu, PhDSub InvestigatorWenying F Zhou, PhDSub InvestigatorJing F Kan, MBBSPrincipal InvestigatorJinque F Luo, PhDSub InvestigatorZhen M Ge, MDPrincipal InvestigatorXiaobo M Li, MDPrincipal InvestigatorXiaofei M Gao, MDPrincipal InvestigatorXiangquan M Kong, MDSub InvestigatorMinghui F Li, PhDSub InvestigatorJuan F Zhang, MDPrincipal InvestigatorLinlin F Zhu, MDPrincipal Investigator